Motus GI Holdings, Inc. (MOTS): History, Ownership, Mission, How It Works & Makes Money

How did Motus GI Holdings, Inc. (MOTS), a medical technology company with a genuinely innovative product like the Pure-Vu® System, go from a promising solution for poor colonoscopy visualization to ceasing operations? You're looking at a classic case study in medtech commercialization, where a great mission-improving clinical outcomes with cost-effective solutions-collided hard with brutal financial realities.

The company's struggle is starkly visible in its final reported numbers: a Q1 2024 revenue of only $64,000 against a net loss of $7.6 million, a gap that made its sub-$209K market capitalization unsustainable by mid-2024. To be fair, that is defintely a tough spot.

Understanding Motus GI Holdings' history, its reliance on selling single-use disposable sleeves for revenue, and the ownership structure that couldn't secure the necessary capital offers crucial lessons for any investor or strategist evaluating high-risk, high-reward medical device startups.

Motus GI Holdings, Inc. (MOTS) History

You need to understand the full arc of a company, not just its product. Motus GI Holdings, Inc.'s story is a classic, albeit tough, lesson in medtech: innovation is only half the battle; commercialization and financial sustainability are the rest. The company, which focused on the Pure-Vu® System to improve colonoscopy visualization, ultimately had its assets acquired in 2024 after a bankruptcy filing, marking a definitive end to its independent journey by the time we hit November 2025.

Given Company's Founding Timeline

Year established

The original technology development began in Israel with the predecessor entity, Motus GI Medical Technologies Ltd., founded in 2008. The current holding company, Motus GI Holdings, Inc., was formally incorporated in Delaware in 2016 as part of a reorganization to prepare for its public offering.

Original location

Initial research and development were centered in Tirat Carmel, Israel. The corporate headquarters later moved to Fort Lauderdale, Florida, USA, to better manage commercialization efforts in the crucial U.S. market.

Founding team members

While the company emerged from the vibrant Israeli medtech ecosystem, the specific individuals who founded the 2008 entity are not widely publicized in the public record. The focus quickly shifted to the executive team driving the regulatory and commercial strategy.

Initial capital/funding

Before its public listing, the company was financed through private investment rounds, raising a total funding of approximately $30.1 million over three rounds. A key funding event was the 2018 Initial Public Offering (IPO), which raised about $17.3 million in net proceeds.

Given Company's Evolution Milestones

Given Company's Transformative Moments

The company's trajectory was shaped by two major pivots: the shift from a development-stage entity to a commercial one, and the final, harsh reality of a strategic exit due to financial constraints. The story pivots around the product's regulatory success but market failure.

• Regulatory Validation (2016-2018): Securing the CE Mark in 2016 and the critical FDA De Novo classification in 2018 was the company's high-water mark. This transformed Motus GI from a concept into a viable medtech player with a product authorized for major global markets.
• The IPO and Capital Infusion (2018): Going public provided the necessary growth capital, but it also exposed the company to the relentless pressure of quarterly results and public market volatility, which it defintely struggled to manage.
• The 2024 Financial Collapse and Acquisition: This was the ultimate transformative moment. Despite the technology's promise-the Pure-Vu System was shown to improve visualization from a baseline of 38% to 96% in clinical studies-the company could not achieve commercial scale. The Chapter 7 bankruptcy filing in May 2024 and the subsequent sale of the Pure-Vu assets to CONMED Corporation for roughly $14 million in the first quarter of 2024 closed the book on Motus GI Holdings, Inc. as an independent entity.

Here's the quick math: The company raised over $30 million in private funding plus $17.3 million from its IPO, but its core assets ultimately sold for only $14 million. That's a stark reminder that technology alone doesn't guarantee a return. For a deeper dive into what went wrong financially, you should read Breaking Down Motus GI Holdings, Inc. (MOTS) Financial Health: Key Insights for Investors.

Motus GI Holdings, Inc. (MOTS) Ownership Structure

Motus GI Holdings, Inc. is a publicly traded company, though its operational status as of November 2025 is defined by an ongoing business wind-down process initiated in mid-2024. This means the company is currently managed by a single director focused on liquidating assets and settling affairs, fundamentally altering the traditional decision-making structure driven by a full board and executive team.

Motus GI Holdings' Current Status

You need to understand that Motus GI Holdings, Inc. (MOTS) is a publicly held medical technology company, but its stock is now traded Over-The-Counter (OTCQB, formerly NASDAQ) following significant financial distress and a strategic shift. The most critical fact is that the company's Board of Directors approved the decision to wind down its business operations in July 2024. This move followed an unsuccessful attempt to secure a quorum for a special stockholders meeting, which essentially signaled the end of its independent operating phase. The core technology, the Pure-Vu System, was acquired by CONMED Corporation in early 2024, further limiting the independent company's scope. Honestly, the company's current status is one of a shell entity managing its final affairs.

Motus GI Holdings' Ownership Breakdown

The ownership breakdown, based on the last available filings for the 2025 fiscal year, shows a highly fragmented shareholder base, which is common for smaller, distressed public companies. Retail investors hold the vast majority of the shares. Here's the quick math on the breakdown, which reflects the structure before the wind-down process fully concluded:

What this estimate hides is the impact of the wind-down; the value of these ownership stakes is now tied directly to the liquidation value of the remaining assets, not future business growth. You can explore the former strategic goals at Mission Statement, Vision, & Core Values of Motus GI Holdings, Inc. (MOTS).

Motus GI Holdings' Leadership

The leadership structure changed dramatically in July 2024, moving from a full executive team and board to a singular focus on the wind-down. The prior CEO and most directors resigned on July 31, 2024. This is a defintely simplified command structure.

As of November 2025, the company is steered by one individual whose mandate is to manage the orderly cessation of business operations and legal compliance. The key leader is:

• Jeff Varsalone: Sole Director and President. His role is purely administrative, focusing on the wind-down of the company's business affairs according to legal requirements, not on strategic growth or product development.

The former leadership, including CEO Mark Pomeranz and Chairman Timothy Moran, stepped down to pursue other opportunities, leaving the company in the hands of the sole director for the final phase of its existence.

Motus GI Holdings, Inc. (MOTS) Mission and Values

The core purpose of Motus GI Holdings, Inc. centered on a noble goal: revolutionizing gastrointestinal endoscopy to improve patient safety and clinical outcomes, but this mission ultimately succumbed to severe financial distress in 2024. Understanding their stated values is key to grasping the ambition that preceded the company's Chapter 7 bankruptcy filing.

Motus GI Holdings, Inc.'s Core Purpose

You're looking at what Motus GI Holdings stood for, and it was a mission-driven medtech company focused on a critical, unmet need in healthcare. The company's entire cultural DNA was built around making the colonoscopy procedure-a cornerstone of colorectal cancer prevention-more effective and less costly for the system. That's a powerful driver, but still, a mission alone doesn't pay the bills.

Official mission statement

The company's formal mission was clear and comprehensive, targeting the entire healthcare ecosystem-patients, providers, and payers. It was about delivering tangible clinical and economic benefits globally, primarily through its Pure-Vu® System.

• Provide innovative solutions to address unmet needs in GI endoscopy.
• Cost-effectively improve clinical outcomes that benefit patients, providers, and payers worldwide.

Here's the quick math: improving visualization during a colonoscopy means fewer missed polyps, which translates to fewer repeat procedures and lower long-term cancer treatment costs. That's the value proposition, and it's a strong one.

Vision statement

Motus GI Holdings' vision was not just to sell a device, but to fundamentally change the standard of care. They aimed to be the new benchmark for how these critical procedures are performed.

• Transform colonoscopy procedures.
• Set a new standard in the detection of colorectal cancer and other gastrointestinal diseases.
• Pioneer the development and adoption of advanced colonoscopy technologies.

To be fair, setting a new standard requires significant capital and market adoption, and the company's last reported quarterly revenue of only $61,000 in Q1 2024, with a net loss of $5.1 million, shows the massive disconnect between vision and commercial reality.

Motus GI Holdings, Inc. Core Values

The company structured its internal culture around four core values, all starting with the letter 'P'. These values guided the team developing and commercializing the Pure-Vu System, a medical device cleared by the U.S. Food and Drug Administration (FDA) to facilitate cleansing of a poorly prepared GI tract.

• People: Value our team and their diversity.
• Passion: Committed to improving patients' lives.
• Pride: Instill care and quality in all we do.
• Performance: Persevere to deliver all of our commitments.

What this estimate hides is that despite the commitment to Performance, the company ultimately ceased operations and filed for Chapter 7 bankruptcy in May 2024, unable to secure the defintely needed immediate funding or a strategic transaction.

Given Company slogan/tagline

While an official, consumer-facing slogan is not widely publicized, the company's investor and product materials often conveyed a simple, supportive message that captured their service-oriented approach to healthcare providers: Exploring Motus GI Holdings, Inc. (MOTS) Investor Profile: Who's Buying and Why?

• We're Here to Help.

It's a straightforward, empathetic statement, but it's a reminder that even a clear mission and strong values can't overcome a lack of commercial traction and a cash crunch. Finance: recognize that a strong mission is a necessary but insufficient condition for survival.

Motus GI Holdings, Inc. (MOTS) How It Works

You need to know how the technology works now, and the blunt truth is that Motus GI Holdings, Inc. (MOTS) is no longer an independent operating entity as of November 2025. The company filed for Chapter 11 bankruptcy in early 2024, and its core asset, the Pure-Vu® System, was acquired by CONMED Corporation for approximately $14 million, so its value creation is now part of CONMED's General Surgery segment.

The system itself, however, is a high-value medical device that works by providing intra-procedural cleansing of the gastrointestinal (GI) tract. It is a single-use, disposable sleeve that attaches to standard endoscopes, using proprietary technology to clear blood, clots, and feces to improve visualization during colonoscopies and emergent upper GI endoscopies.

Given Company's Product/Service Portfolio

The entire product portfolio revolves around the Pure-Vu® EVS System, which is designed to solve the critical problem of inadequate visualization during endoscopy procedures. The company's former revenue model was based on selling the main workstation and then generating recurring revenue from the sale of these disposable sleeves.

Given Company's Operational Framework

The operational framework for the Pure-Vu System is now deeply embedded within the global supply chain and sales infrastructure of CONMED Corporation. The original Motus GI Holdings, Inc. struggled with a direct sales model and capital constraints, reporting only $61,000 in revenue and a net loss of $5.1 million in Q1 2024 before the sale.

Here's the quick math on the shift: CONMED, the new owner, is a much larger entity, with full-year 2025 revenue expected to be between $1.365 billion and $1.372 billion. This provides the scale and financial runway the Pure-Vu System defintely needed to succeed. The value is created through a razor-and-blade model: selling the capital equipment (workstation) and then the high-margin, single-use disposable sleeves for each procedure.

• Manufacturing & Supply: Leverage CONMED's existing, larger-scale production and quality control systems to lower the cost-of-goods, a key improvement over the original company's operations.
• Distribution: Utilize CONMED's established domestic and international sales channels, which reach over 6,000 hospitals and surgery centers globally, accelerating market penetration.
• Commercialization: Focus on the U.S. market first, with plans for commercial activities in Europe expected to start in 2025.

For a deeper dive into the former company's strategic goals, you can look at the historical documents: Mission Statement, Vision, & Core Values of Motus GI Holdings, Inc. (MOTS).

Given Company's Strategic Advantages

The Pure-Vu System's strategic advantage is its unique technological solution to a persistent clinical problem, now amplified by the financial and commercial power of CONMED. It's a niche product solving a high-acuity problem.

• Proprietary Cleansing Technology: It is the only system with 5 pressure-controlled irrigation jets that create a pulsed vortex of air and water to break up debris, plus a smart sense suction feature to prevent clogging.
• Dual-Indication Platform: The system addresses both challenging colonoscopies and emergent upper GI bleeds, expanding the total addressable market significantly for the new owner.
• Enhanced Market Access: The shift to CONMED, a company with Q3 2025 sales of $337.9 million, provides immediate access to major hospital networks and Group Purchasing Organizations (GPOs) that the small, former entity could not penetrate effectively.
• Procedural Efficiency: By improving visualization, the system reduces the incidence of delayed, aborted, or incomplete procedures, which translates directly to cost savings and increased throughput for hospitals.

Motus GI Holdings, Inc. (MOTS) How It Makes Money

Motus GI Holdings, Inc. generated revenue by commercializing its Pure-Vu System, a medical device designed to clear debris and improve visualization during colonoscopy and upper GI endoscopy procedures. The core of their financial model relied on a classic razor-and-blades approach, selling the main workstation (the razor) and then generating recurring revenue from the proprietary, single-use disposable sleeves (the blades) required for each patient procedure.

You need to know the reality: Motus GI Holdings, Inc. ceased independent operations and filed for Chapter 7 bankruptcy in May 2024, with its assets, including the Pure-Vu System technology, acquired by CONMED Corporation in the first quarter of 2024. Therefore, the following financial breakdown is based on the last full fiscal year for the independent entity, 2023, as 2025 data for Motus GI Holdings, Inc. does not exist.

Given Company's Revenue Breakdown (Based on FY 2023 Data)

The total revenue for Motus GI Holdings, Inc. in the fiscal year ended December 31, 2023, was $319,000, a -46.11% decrease from the prior year. The revenue was primarily driven by the recurring sales of disposable sleeves.

Business Economics

The economic fundamentals were built on the idea of solving a costly problem: inadequate bowel preparation, which leads to repeat procedures, longer hospital stays, and missed lesions. The Pure-Vu System aimed to make the procedure successful the first time, especially for inpatients. This value proposition was the key to justifying the capital expense and the per-procedure cost of the disposable sleeve.

• Razor-and-Blades Model: Initial system placement-either via sale or lease-was the entry point, but the long-term profitability hinged on the high-margin, single-use disposable sleeves.
• Cost of Revenue: The cost of revenue was $570,000 in 2023, resulting in a negative gross profit (or gross loss) of -$251,000. This means the company was selling its products for less than the direct cost to manufacture them, a significant red flag.
• Pricing Strategy: The pricing of the disposable sleeves had to be low enough for hospitals to adopt the technology but high enough to cover the high operating costs of a small medtech company. The economic argument for hospitals was a reduction in total healthcare costs-fewer repeat colonoscopies, shorter hospital stays-which was supposed to offset the cost of the disposable.
• Market Niche: The technology targeted the niche of poorly prepped patients, particularly in the inpatient setting where up to 51% of procedures were delayed due to preparation issues.

The margin structure was simply unsustainable at the reported sales volume. Mission Statement, Vision, & Core Values of Motus GI Holdings, Inc. (MOTS).

Given Company's Financial Performance (Based on FY 2023 Data)

The financial performance leading up to the company's cessation of operations showed severe distress. The business was highly cash-consumptive and failed to reach the commercial scale needed to cover its operating expenses.

• Revenue Decline: Total revenue fell to just $319,000 in 2023, down from $592,000 in 2022. That's a huge drop, and it shows commercial adoption was stalling.
• Net Loss: The company reported a net loss of -$12.87 million for the full year 2023, a slight improvement from the -$18.6 million loss in 2022, but still far from profitability.
• Operating Expenses: Even with low revenue, operating expenses remained high at $11.66 million in 2023, driven by Selling, General & Administrative costs of $8.19 million and R&D expenses of $3.47 million.
• Cash Burn: Net cash used in operating activities and for the purchase of fixed assets totaled $11.3 million in 2023. This cash burn rate, against a revenue of only $319,000, is the quick math that signals an existential crisis.

The company simply ran out of cash to sustain its operations and commercialization efforts, leading to the acquisition of its technology by CONMED Corporation in 2024 for approximately $14 million. That's the final, defintely concrete number in this story.

Motus GI Holdings, Inc. (MOTS) Market Position & Future Outlook

You need to know the reality: Motus GI Holdings, Inc. (MOTS) is no longer an independent operating entity as of November 2025, having filed for bankruptcy and sold its assets, including the core Pure-Vu System technology, to CONMED Corporation for approximately $14 million in early 2024. The future outlook for this technology is now entirely mapped to CONMED's strategy within its General Surgery segment, which is expected to drive a portion of CONMED's projected $1.356 billion to $1.378 billion in total 2025 revenue. The Pure-Vu System's value lies in its niche: solving the critical, costly problem of inadequate bowel preparation during colonoscopies.

Competitive Landscape

The Pure-Vu System operates in a unique niche-intra-procedural cleansing-where it has a near-monopoly due to its patented design. It is an accessory to the main GI Endoscopy market, which is dominated by giants. The real competition comes from the established players who control the overall capital equipment (endoscope) and therapeutic device ecosystem. The technology's market share, as a single accessory, is small, likely under 1% of the total U.S. GI Endoscopic Devices Market, which was valued at over $5.9 billion in 2023.

Opportunities & Challenges

The Pure-Vu System's future is a classic case of niche technology gaining scale under a major player. The opportunity is huge, but the integration process presents real, near-term challenges. Honestly, the biggest opportunity is simply having CONMED's sales force behind it now.

Industry Position

The Pure-Vu System, as part of CONMED's General Surgery portfolio, is positioned as a high-margin, single-use disposable product that addresses a massive clinical pain point: the high cost and poor outcomes of incomplete colonoscopies. The asset's value is not its independent revenue (which was only $3.4 million in 2024 for the original company), but its ability to improve the workflow and economics of a procedure that costs the healthcare system billions. CONMED's General Surgery segment, which houses this technology, reported $201.6 million in Q2 2025 revenue, up 4.7% year-over-year, and the Pure-Vu System is a key growth driver in that segment.

• High-Value Niche: The technology is the only FDA-cleared device for on-demand, intra-procedural cleansing, giving it a first-mover advantage.
• Financial Leverage: It shifts the cost-benefit analysis for hospitals by reducing the need for costly repeat procedures, which is a strong selling point for CONMED's sales team.
• Growth Trajectory: The broader global endoscopy market is estimated to be valued at $40.10 billion in 2025, with GI endoscopy making up over half of that, so the runway for a niche solution is long.

To be fair, the technology needs to move from a niche solution for 'rescue' cases to a standard-of-care tool. That's the defintely the next hurdle for CONMED. You can find more detail on the company's past financial performance and the context of the acquisition here: Breaking Down Motus GI Holdings, Inc. (MOTS) Financial Health: Key Insights for Investors